Description of hypersensitivity adverse events following administration of heparin that was potentially contaminated with oversulfated chondroitin sulfate in early 2008

Pharmacoepidemiology and Drug Safety

Volumn 19, Issue 9, 2010, Pages 921-933

  McMahon, Ann W ^a   Pratt, Robert G ^a   Hammad, Tarek A ^a   Kozlowski, Steven ^a   Zhou, Esther ^a   Lu, Susan ^a   Kulick, Corrinne G ^a   Mallick, Tarun ^a,b   Dal Pan, Gerald ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b WORLD BANK   (United States)

Author keywords

Adverse events; Contamination; Heparin

Indexed keywords

CHONDROITIN SULFATE; HEPARIN; OVERSULFATED CHONDROITIN SULFATE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ANGIONEUROTIC EDEMA; ARTICLE; BLOOD CLOTTING TIME; BLOOD PRESSURE; BURNING SENSATION; CHILD; COUGHING; DIARRHEA; DIZZINESS; DRUG CONTAMINATION; DRUG EFFECT; DRUG HYPERSENSITIVITY; DYSPNEA; FACE EDEMA; FATALITY; FEELING HOT; FEMALE; FLUSHING; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERHIDROSIS; HYPOTENSION; LIP SWELLING; MAJOR CLINICAL STUDY; MALE; MORTALITY; NAUSEA; NEUROLOGIC DISEASE; ORAL PARESTHESIA; PARESTHESIA; PHARYNX EDEMA; PRIORITY JOURNAL; PRURITUS; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SKIN MANIFESTATION; TONGUE SWELLING; UNCONSCIOUSNESS; UNRESPONSIVE TO STIMULUS; UPPER ABDOMINAL PAIN; URTICARIA; VOMITING;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; CHILD; CHILD, PRESCHOOL; CHONDROITIN SULFATES; DRUG CONTAMINATION; DRUG HYPERSENSITIVITY; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; YOUNG ADULT;

EID: 77957332662     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1991     Document Type: Article

References (16)

1. Turabelidze G, Elward A, Jones M, Patel PR, Arduino M, Gould C, Shehab N, Sunkavalli K, Schillie S, Blossom D, Kallen A, Jaeger J. Acute allergic-type reactions among patients undergoing hemodialysis - multiple states, 2007-2008. MMWR Morb Mortal Wkly Rep 2008; 57(5): 124-125.
2. Blossom DB, Kallen AJ, Patel PR, et al. Outbreak of adverse reactions associated with contaminated heparin. N Engl J Med 2008; 359(25): 2674-2684.
3. Recall - firm press release: Baxter issues urgent nationwide voluntary recall of heparin 1,000 units/ml 10 and 30 ml multi-dose vials. Rockville, MD: Food and Drug Administration, 2008 (Accessed October 23, 2009 at http://www.fda.gov/Safety/Recalls/ArchiveRecalls/2008/ucm112352.htm).
4. Recall - firm press release: Baxter to proceed with recall of remaining heparin sodium vial products. Rockville, MD: Food and Drug Administration, 2008 (Accessed October 23, 2009 at http://www.fda.gov/Safety/Recalls/ArchiveRecalls/ 2008/ucm112384.htm).
5. Kishimoto TK, Viswanathan K, Ganguly T, et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 2008; 358(23): 2457-2467. (Pubitemid 351793019)
6. Rodriguez E, Staffa J, Graham D. The role of databases in drug postmarketing surveillance. Pharmacoepidemiol Drug Saf 2001; 10(5): 407-410.
7. Tami C, Puig M, Reepmeyer JC, et al. Inhibition of Taq polymerase as a method for screening heparin for oversulfated contaminants. Biomaterials 2008; 29(36): 4808-4814.
8. Patel RP, Narkowicz C, Hutchinson JP, Hilder EF, Jacobson GA. A simple capillary electrophoresis method for the rapid separation and determination of intact low molecular weight and unfractionated heparins. J Pharm Biomed Anal 2008; 46(1): 30-35.
9. Trehy ML, Reepmeyer JC, Kolinski RE, Westenberger BJ, Buhse LF. Analysis of heparin sodium by SAX/HPLC for contaminants and impurities. J Pharm Biomed Anal 2009; 49(3): 670-673.
10. Varricchio F, Iskander J, Destefano F, et al. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J 2004; 23: 287-294. (Pubitemid 38508877)
11. FDAMedia Briefing on Heparin. February 28, 2008; http://www.fda.gov/ downloads/NewsEvents/Newsroom/MediaTranscripts/UCM169342.pdf.
12. Tanja B, Magnus M, Daniela B, et al. Composition of OSCS-contaminated heparin occurring in 2008 in batches on the German market. Eur J Pharm Sci 2010; 40: 297-304.
13. Arepally GM, Ortel TL. Heparin-induced thrombocytopenia. N Engl J Med 2006; 355: 809-817.
14. Goldman SA. Limitations and strengths of spontaneous reports data. Clin Ther 1998; 20(Suppl C): C40-C44.
15. Hartung DM, Touchette D. Overview of clinical research design. Am J Health Syst Pharm 2009; 66(4): 398-408.
16. Platt R, Wilson M, Chan KA, Benner JS, Marchibroda J, McClellan M. The new Sentinel Network - improving the evidence of medicalproduct safety. N Engl J Med 2009; 361(7): 645-647.